Structure assessment of heterogeneous polypeptide mixture

Patent metadata

Field	Value
Publication number	US-9714898-B2
Application number	US-201514816730-A
Country	US
Kind code	B2
Filing date	Aug 3, 2015
Priority date	Jul 11, 2011
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

A method of manufacturing a glatiramer acetate drug product is described. The method entails measuring one or both of alpha helical content of the glatiramer acetate and random coil content of the glatiramer acetate in the batch and manufacturing a glatiramer acetate drug product using at least a portion of the glatiramer acetate when the alpha helical content and or random coil content meets certain criteria.

First claim

The invention claimed is:

1. A method of manufacturing a glatiramer acetate drug product, the method comprising:
(a) providing a batch of a composition comprising glatiramer acetate;
(b) measuring one or both of alpha helical content of the glatiramer acetate and random coil content of the glatiramer acetate in the batch; and
(c) manufacturing a glatiramer acetate drug product using at least a portion of the batch only if: i) the measured alpha helical content of glatiramer acetate in the batch is 53.8% to 65.0% under reference conditions, ii) the measured random coil content of glatiramer acetate in the batch is 46.2% to 35.0% under reference conditions, or iii) the measured alpha helical content of glatiramer acetate in the batch is 53.8% to 65.0% under reference conditions and the measured random coil content of glatiramer acetate in the batch is 46.2% to 35.0% under reference conditions, wherein the reference conditions are 5° C. in 10 mM sodium phosphate at pH 7.0,
wherein the step of manufacturing a glatiramer acetate drug product comprises adding mannitol to at least a portion of the batch.

2. The method of claim 1 wherein the step of providing a batch of a composition comprising glatiramer acetate comprises: polymerizing an N-carboxy anhydride of L-alanine, an N-carboxy anhydride of benzyl-protected L-glutamic acid, an N-carboxy anhydride of trifluoroacetic acid (TFA) protected L-lysine and an N-carboxy anhydride of L-tyrosine to generate a protected copolymer; and treating the protected copolymer to partially depolymerize the protected copolymer, deprotect benzyl protected groups and deprotect TFA-protected lysines.

3. A method of preparing a pharmaceutical composition comprising glatiramer acetate, the method comprising:
(a) providing a batch of a composition comprising a copolymer of tyrosine, lysine, alanine and glutamic acid;
(b) measuring one or both of alpha helical content of the copolymer and random coil content of the copolymer in the batch; and
(c) preparing a pharmaceutical composition comprising glatiramer acetate using at least a portion of the batch only if: i) the measured alpha helical content of copolymer in the batch is 53.8% to 65.0% under reference conditions, ii) the measured random coil content of copolymer in the batch is 46.2% to 35.0% under reference conditions, or iii) the measured alpha helical content of copolymer in the batch is 53.8% to 65.0% under reference conditions and the measured random coil content of copolymer in the batch is 46.2% to 35.0% under reference conditions, wherein the reference conditions 5° C. in 10 mM sodium phosphate at pH 7.0,
wherein the step of preparing a pharmaceutical composition comprising adding mannitol.

4. The method of claim 3 wherein the step of providing a batch of a composition comprising a copolymer of tyrosine, lysine, alanine and glutamic acid comprises:
polymerizing an N-carboxy anhydride of L-alanine, an N-carboxy anhydride of benzyl-protected L-glutamic acid, an N-carboxy anhydride of trifluoroacetic acid (TFA) protected L-lysine and an N-carboxy anhydride of L-tyrosine to generate a protected copolymer; and treating the protected copolymer to partially depolymerize the protected copolymer, deprotect benzyl protected groups and deprotect TFA-protected lysines.

5. The method of claim 3 wherein the copolymer is glatiramer acetate drug substance.

Assignees

• Momenta Pharmaceuticals Inc

Inventors

• Sridharan Ramamurthi

Classifications

• C07K14/001

  by chemical synthesis · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• C07K1/061

  using protecting groups · CPC title

• G01N21/25

  Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands · CPC title

• Y10S514/903

  Cross-Sectional Technologies · mapped topic